CARs Moving Forward: The Development of CAR T-Cell Therapy in the Earlier Treatment Course of Hematologic Malignancies
Authors:
- 24 August 2024
- journal article
- research article
- Published by Elsevier in Seminars in Hematology
- Vol. 61 (5) , 290-296
Abstract
No abstract availableKeywords
This publication has 82 references indexed in Scilit:
- TRANSCEND FL: PHASE 2 STUDY RESULTS OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)Hematological Oncology, 2023
- MRD‐NEGATIVITY AFTER FRONTLINE DLBCL THERAPY: POOLED ANALYSIS OF 6 CLINICAL TRIALSHematological Oncology, 2023
- Ethical Challenges with Multiple Myeloma BCMA Chimeric Antigen Receptor T Cell Slot Allocation: A Multi-Institution ExperienceTransplantation and Cellular Therapy, 2023
- Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell LymphomaJAMA Network Open, 2022
- Transplant-ineligible but chimeric antigen receptor T-cells eligible: a real and relevant populationEuropean Journal of Cancer, 2022
- Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B-cell lymphomaTransplantation and Cellular Therapy, 2022
- KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 studyThe Lancet, 2021
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label studyThe Lancet, 2021
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design studyThe Lancet, 2020
- Diffuse large B‐cell lymphoma with primary treatment failure: Ultra‐high risk features and benchmarking for experimental therapiesAmerican Journal of Hematology, 2016